MCID: PTY001
MIFTS: 44

Pityriasis Rosea

Categories: Skin diseases

Aliases & Classifications for Pityriasis Rosea

MalaCards integrated aliases for Pityriasis Rosea:

Name: Pityriasis Rosea 12 36 43 15 17 71 32
Pityriasis Circinata 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8892
KEGG 36 H01660
ICD9CM 34 696.3
MeSH 43 D017515
NCIt 49 C26855
SNOMED-CT 67 77252004
ICD10 32 L42
UMLS 71 C0032026

Summaries for Pityriasis Rosea

KEGG : 36 Pityriasis rosea (PR) is an acute exanthem, which prevalently affects children and young adults. The cause of PR is uncertain but epidemiological (seasonal variation and clustering in communities) and clinical features suggest an infective agent. Light and electron microscopy findings suggest infection with human herpesviruses 6 and 7 (HHV-6/7). HHV-6 and HHV-7 may also interact with each other, explaining recurrences and atypical presentations. PR is self limiting and resolves within one to three months. It typically starts with the development of a large erythematous scaly plaque also called the herald patch or mother patch on trunk or neck, which is followed by an eruption of multiple secondary small erythematous scaly lesions located predominantly on the trunk and following the lines of cleavage on the back (Christmas tree or inverted fir tree appearance). Collarette scaling is seen typically. The eruption is usually preceded by a prodrome of sore throat, gastrointestinal disturbance, fever, and arthralgia. A case of PR is diagnosed mainly on clinical grounds. A biopsy is needed in atypical cases, and it mainly helps in excluding other differentials rather than diagnosing PR as the histopathological examination in a case of PR is relatively nonspecific and resembles a subacute or chronic dermatitis. As PR is a self-limiting disorder, most patients just need to be counseled regarding the natural course of the disease instead of putting them on an aggressive treatment protocol. Most patients would just need emollients, antihistaminics, and sometimes topical steroids to control pruritus.

MalaCards based summary : Pityriasis Rosea, also known as pityriasis circinata, is related to geographic tongue and syphilis. An important gene associated with Pityriasis Rosea is CX3CL1 (C-X3-C Motif Chemokine Ligand 1), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Petrolatum and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Pityriasis rosea is a type of skin rash. Classically, it begins with a single red and slightly scaly... more...

Related Diseases for Pityriasis Rosea

Diseases related to Pityriasis Rosea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
# Related Disease Score Top Affiliating Genes
1 geographic tongue 30.8 HLA-DQB1 HLA-A
2 syphilis 30.7 HLA-DRB1 HLA-C CD40LG
3 psoriasis 30.5 HLA-DRB1 HLA-C HLA-B HLA-A
4 skin disease 30.2 HLA-C HLA-B CD40LG CD1A
5 seborrheic dermatitis 30.1 CD1E CD1A
6 herpes zoster 30.0 HLA-DRB1 HLA-B HLA-A CD40LG
7 pemphigus 29.9 HLA-DRB1 HLA-DQB1 CD40LG
8 aplastic anemia 29.8 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
9 vasculitis 29.7 HLA-B CX3CL1 CD40LG
10 measles 29.6 HLA-DRB1 HLA-A CD40LG
11 pharyngitis 29.6 HLA-DRB1 CD40LG CD1A
12 myocarditis 29.3 HLA-DRB4 HLA-DQB1 HLA-B CD40LG
13 behcet syndrome 29.0 HLA-DRB1 HLA-C HLA-B HLA-A CD40LG
14 autoimmune disease 29.0 HLA-DRB1 HLA-DQB1 HLA-B HLA-A CD40LG
15 leprosy 3 28.9 HLA-DRB1 CD40LG CD1E CD1A
16 rubella 28.7 HLA-DRB1 HLA-DQB1 HLA-C HLA-B HLA-A CD40LG
17 rheumatoid arthritis 28.5 HLA-DRB5 HLA-DRB1 HLA-DQB1 HLA-B CX3CL1 CD40LG
18 exanthem 10.9
19 dermatitis 10.6
20 pustulosis of palm and sole 10.6
21 secondary syphilis 10.5
22 lichen planus 10.5
23 erythema multiforme 10.5
24 microscopic polyangiitis 10.4 HLA-DRB1 CX3CL1
25 limbic encephalitis with lgi1 antibodies 10.4 HLA-DRB1 HLA-DQB1
26 autoimmune polyglandular syndrome type 3 10.4 HLA-DRB1 HLA-DQB1
27 hypersomnia 10.4 HLA-DRB1 HLA-DQB1
28 narcolepsy 2 10.4 HLA-DRB1 HLA-DQB1
29 dowling-degos disease 1 10.4
30 primary adrenal insufficiency 10.4 HLA-DRB1 HLA-DQB1
31 type ii mixed cryoglobulinemia 10.4 HLA-DRB1 HLA-DQB1
32 recurrent respiratory papillomatosis 10.4 HLA-DRB1 HLA-DQB1
33 beryllium disease 10.4 HLA-DRB1 HLA-DQB1
34 apple allergy 10.4 HLA-DRB1 HLA-DQB1
35 chronic beryllium disease 10.4 HLA-DRB1 HLA-DQB1
36 rheumatoid vasculitis 10.4 HLA-DRB1 CX3CL1
37 focal epithelial hyperplasia 10.4 HLA-DRB1 HLA-DQB1
38 pediatric multiple sclerosis 10.4 HLA-DRB1 HLA-DQB1
39 metal allergy 10.4 HLA-DRB1 HLA-DQB1
40 ichthyosis 10.4
41 ige responsiveness, atopic 10.4
42 dermatitis, atopic 10.4
43 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
44 herpes simplex 10.4
45 dermatophytosis 10.4
46 narcolepsy 1 10.4 HLA-DRB1 HLA-DQB1
47 osteonecrosis of the jaw 10.4 HLA-DRB1 HLA-DQB1
48 caplan's syndrome 10.3 HLA-DRB1 HLA-A
49 oligoarticular juvenile idiopathic arthritis 10.3 HLA-DRB1 HLA-DQB1
50 ocular cicatricial pemphigoid 10.3 HLA-DRB1 HLA-DQB1

Graphical network of the top 20 diseases related to Pityriasis Rosea:



Diseases related to Pityriasis Rosea

Symptoms & Phenotypes for Pityriasis Rosea

GenomeRNAi Phenotypes related to Pityriasis Rosea according to GeneCards Suite gene sharing:

26 (show top 50) (show all 56)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 11.17 HLA-A HLA-B HLA-C
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 11.17 HLA-A HLA-B HLA-C
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-113 11.17 HLA-DRB3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 11.17 HLA-DRB4
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-127 11.17 HLA-DRB4
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-128 11.17 HLA-DRB1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 11.17 HLA-C
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 11.17 HLA-A HLA-B HLA-C
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-174 11.17 HLA-DRB4
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 11.17 HLA-A HLA-B HLA-C
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 11.17 HLA-A HLA-B HLA-C
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-2 11.17 HLA-DRB4
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 11.17 HLA-C
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 11.17 HLA-DRB4
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 11.17 HLA-DRB4 HLA-A HLA-B HLA-C
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 11.17 HLA-DRB3
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 11.17 HLA-DRB5
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 11.17 HLA-DRB1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 11.17 HLA-A HLA-B HLA-C
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-80 11.17 HLA-DRB1 HLA-DRB3
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 11.17 HLA-DRB4
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 11.17 HLA-C
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 11.17 HLA-C
24 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.98 HLA-DRB3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-109 9.98 HLA-DRB5
26 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.98 HLA-DRB1 HLA-DRB4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.98 HLA-DRB4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.98 HLA-DRB3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.98 HLA-DRB1 HLA-DRB4
30 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.98 HLA-DRB3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.98 HLA-DRB5
32 Increased shRNA abundance (Z-score > 2) GR00366-A-142 9.98 HLA-DRB1 HLA-DRB4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.98 HLA-DRB4
34 Increased shRNA abundance (Z-score > 2) GR00366-A-150 9.98 HLA-DRB4
35 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.98 HLA-DRB3
36 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.98 HLA-DRB1 HLA-DRB3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.98 HLA-DRB3
38 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.98 HLA-DRB5
39 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.98 HLA-DRB1 HLA-DRB3 HLA-DRB4 HLA-DRB5
40 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.98 HLA-DRB5
41 Increased shRNA abundance (Z-score > 2) GR00366-A-179 9.98 HLA-DRB3
42 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.98 HLA-DRB1 HLA-DRB3 HLA-DRB4
43 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.98 HLA-DRB1 HLA-DRB3 HLA-DRB4
44 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.98 HLA-DRB3
45 Increased shRNA abundance (Z-score > 2) GR00366-A-212 9.98 HLA-DRB4
46 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.98 HLA-DRB4
47 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.98 HLA-DRB3
48 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.98 HLA-DRB4
49 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.98 HLA-DRB3
50 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.98 HLA-DRB4

Drugs & Therapeutics for Pityriasis Rosea

Drugs for Pityriasis Rosea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Petrolatum Approved, Investigational Phase 4 8009-03-8
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
4 Immunosuppressive Agents Phase 4
5 Dermatologic Agents Phase 4
6 Calcineurin Inhibitors Phase 4
7 Hormones Phase 4
8 Vasoconstrictor Agents Phase 4
9 Emollients Phase 4
10 Calcium, Dietary Phase 4
11
Calcium Nutraceutical Phase 4 7440-70-2 271
12
Pimecrolimus Approved, Investigational Phase 2, Phase 3 137071-32-0 17753757 6447131
13 Analgesics, Non-Narcotic Phase 2, Phase 3
14 Analgesics Phase 2, Phase 3
15 Anti-Inflammatory Agents Phase 2, Phase 3
16 Sunscreening Agents Phase 2, Phase 3
17 Antirheumatic Agents Phase 2, Phase 3
18 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
19
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
20 Immunologic Factors
21 Trace Elements
22 Micronutrients
23 Vitamins
24 Nutrients
25 Calciferol
26 Antibodies
27 Immunoglobulins, Intravenous
28 Immunoglobulin E
29 Immunoglobulins

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Double Blind Randomized Trial, Placebo-controled of 0.0003% Calcitriol Ointment Versus 0.1% Tacrolimus Ointment in the Treatment of Pityriasis Alba Completed NCT01388517 Phase 4 Tacrolimus;Calcitriol;Petrolatum
2 Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba: A Randomized Placebo-controlled Trial Not yet recruiting NCT03834935 Phase 2, Phase 3 Elidel (pimecrolimus 1%);Cold Cream
3 Serum 25(OH) Vitamin D and Total Serum Immunoglobulin E Levels in Patients With Pityriasis Alba Active, not recruiting NCT03443765

Search NIH Clinical Center for Pityriasis Rosea

Inferred drug relations via UMLS 71 / NDF-RT 50 :


methdilazine
Methdilazine hydrochloride

Cochrane evidence based reviews: pityriasis rosea

Genetic Tests for Pityriasis Rosea

Anatomical Context for Pityriasis Rosea

MalaCards organs/tissues related to Pityriasis Rosea:

40
Skin, T Cells, Testes, Bone Marrow, Bone, Breast, Tonsil

Publications for Pityriasis Rosea

Articles related to Pityriasis Rosea:

(show top 50) (show all 642)
# Title Authors PMID Year
1
Dermoscopy in differential diagnosis of inflammatory dermatoses and mycosis fungoides. 61
32406102 2020
2
Change of the diagnostic distribution in applicants to dermatology after COVID-19 pandemic: What it whispers to us? 61
32530503 2020
3
The Clinics of HHV-6 infection in COVID-19 pandemic: Pityriasis rosea and Kawasaki disease. 61
32475003 2020
4
Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children. 61
32455505 2020
5
HHV 6-7 reactivation causing Pityriasis Rosea and labyrinthitis: A case report. 61
32553563 2020
6
Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. 61
32359180 2020
7
Pityriasis Rosea: Risk and Treatment During Pregnancy. 61
32208015 2020
8
Unilateral pityriasis rosea. 61
31646609 2020
9
Acute exanthemas: a prospective study of 98 adult patients with an emphasis on cytokinic and metagenomic investigation. 61
31127953 2020
10
Pityriasis rosea and other infectious eruptions during pregnancy: Possible life-threatening health conditions for the fetus. 61
32197740 2020
11
The rash with mucosal ulceration. 61
32197747 2020
12
Histopathologic features distinguishing secondary syphilis from its mimickers. 61
31306731 2020
13
Dermatologic Problems Commonly Seen by the Allergist/Immunologist. 61
31351991 2020
14
Evaluation of thiol/disulfide homeostasis in patients with pityriasis rosea. 61
31092070 2019
15
Is there a relationship between environmental factors and pityriasis rosea? Reply to Singh et al. 61
31854956 2019
16
Reply to: comment on “Is there a relationship between environmental factors and pityriasis rosea?” 61
31854957 2019
17
Inverse Pityriasis Rosea. 61
31729335 2019
18
Interventions for pityriasis rosea. 61
31684696 2019
19
Commentary on: "Pityriasis Rosea Recurrence is Much Higher than Previously Known: A Prospective Study". 61
31304559 2019
20
Epidermotropic CXCR3 positive marginal zone lymphoma: a distinctive clinical histopathological entity potentially originating in the skin; it does not always indicate splenic marginal zone lymphoma. 61
31450275 2019
21
Classification of Skin Disease using Ensemble Data Mining Techniques. 61
31244314 2019
22
Pityriasis Rosea Recurrence is Much Higher than Previously Known: A Prospective Study. 61
30848285 2019
23
The efficacy of oral acyclovir during early course of pityriasis rosea: a systematic review and meta-analysis. 61
30109959 2019
24
Does influenza subtype H1N1 have a place in the etiology of pityriasis rosea? 61
31320848 2019
25
Pityriasis rosea: elucidation of environmental factors in modulated autoagressive etiology and dengue virus infection. 61
30901064 2019
26
Simultaneous occurrence of hand, foot and mouth disease and pityriasis rosea: double viral exanthem. 61
29144097 2019
27
Otalgia, Preeclampsia, Latent Tuberculosis, Pityriasis Rosea, Extremity Pain. 61
30763052 2019
28
Dermoscopic Features of Psoriasis, Lichen Planus, and Pityriasis Rosea in Patients With Skin Type IV and Darker Attending the Regional Dermatology Training Centre in Northern Tanzania. 61
30775148 2019
29
Using Neural Networks for Diagnosing in Dermatology. 61
31156118 2019
30
Subsets of T lymphocytes in the lesional skin of pityriasis rosea. 61
30726464 2019
31
Pityriasis Rosea. 61
30383122 2018
32
Pityriasis Rosea: Clinical Profile from Central India. 61
30505781 2018
33
Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea. 61
29363373 2018
34
Annular Lesions: Diagnosis and Treatment. 61
30216021 2018
35
Incidence of diseases primarily affecting the skin by age group: population-based epidemiologic study in Olmsted County, Minnesota, and comparison with age-specific incidence rates worldwide. 61
29377079 2018
36
Anetodermic lesions following pityriasis rosea and impetigo. 61
30229641 2018
37
Effectiveness of acyclovir in the treatment of pityriasis rosea. A systematic review and meta-analysis. 61
30156618 2018
38
Pityriasis rosea and pityriasis rosea-like eruptions: How to distinguish them? 61
30246131 2018
39
Association of HLA-DQB1*03:03 with pityriasis rosea in Chinese patients. 61
29222811 2018
40
Pityriasis rosea-like eruption associated with ondansetron use in pregnancy. 61
29520857 2018
41
Relapsing Pityriasis Rosea With HHV-7 Reactivation in an 11-Year-Old Girl. 61
29674359 2018
42
Recurrent pityriasis rosea: A case report. 61
29182459 2018
43
Pityriasis Rosea in a Mother and her Daughter: A Case Report. 61
29644205 2018
44
Pityriasis rosea-like eruption induced by isotretinoin. 61
28359163 2018
45
Geographic tonguelike presentation in a child with pityriasis rosea: Case report and review of oral manifestations of pityriasis rosea. 61
29436009 2018
46
Pityriasis rosea in a patient with retrovirus infection: a reply. 61
29599683 2018
47
Efficacy and Safety of Indigo Naturalis in Combination with Narrow-Band Ultraviolet B for Treatment of Pityriasis Rosea: A Meta-Analysis. 61
29770152 2018
48
Pityriasis Rosea during Pregnancy: Major and Minor Alarming Signs. 61
29936509 2018
49
Pityriasis Rosea. 61
29431416 2018
50
Pityriasis Rosea. 61
29365248 2018

Variations for Pityriasis Rosea

Expression for Pityriasis Rosea

Search GEO for disease gene expression data for Pityriasis Rosea.

Pathways for Pityriasis Rosea

Pathways related to Pityriasis Rosea according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
2
Show member pathways
13.37 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
3
Show member pathways
13.3 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
4
Show member pathways
13.04 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
5
Show member pathways
12.91 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
6
Show member pathways
12.82 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
7
Show member pathways
12.77 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
8 12.73 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
9
Show member pathways
12.72 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
10
Show member pathways
12.65 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 CD40LG
11
Show member pathways
12.57 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
12
Show member pathways
12.46 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
13
Show member pathways
12.42 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 CD40LG
14
Show member pathways
12.37 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
15
Show member pathways
12.28 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 CD40LG
16 12.27 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
17
Show member pathways
12.24 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
18 12.2 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
19 12.14 HLA-C HLA-B HLA-A
20 12.12 HLA-C HLA-B HLA-A CD40LG CD1A
21 12.02 HLA-C HLA-B HLA-A
22
Show member pathways
12.02 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
23 11.99 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
24 11.98 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
25 11.94 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
26 11.91 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
27 11.76 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
28
Show member pathways
11.76 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
29 11.74 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
30 11.7 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 CD1E
31 11.45 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
32 11.2 HLA-C HLA-B HLA-A
33 11.16 CX3CL1 CD40LG

GO Terms for Pityriasis Rosea

Cellular components related to Pityriasis Rosea according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.34 HLA-DRB5 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C HLA-B
2 integral component of membrane GO:0016021 10.27 HLA-DRB5 HLA-DRB1 HLA-DQB1 HLA-C HLA-B HLA-A
3 plasma membrane GO:0005886 10.23 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
4 integral component of plasma membrane GO:0005887 10.1 HLA-DRB3 HLA-DRB1 HLA-C HLA-B HLA-A CD40LG
5 Golgi apparatus GO:0005794 10.06 HLA-DRB5 HLA-DRB1 HLA-C HLA-B HLA-A CD1E
6 endoplasmic reticulum membrane GO:0005789 10.01 HLA-DRB5 HLA-DRB1 HLA-C HLA-B HLA-A
7 cell surface GO:0009986 9.99 HLA-DRB1 HLA-C HLA-B HLA-A CX3CL1 CD40LG
8 lysosomal membrane GO:0005765 9.92 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
9 Golgi membrane GO:0000139 9.91 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
10 external side of plasma membrane GO:0009897 9.89 HLA-DRB1 CD40LG CD1E CD1A
11 endosome membrane GO:0010008 9.85 HLA-DRB5 HLA-DRB1 HLA-DQB1 CD1A
12 late endosome membrane GO:0031902 9.84 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1
13 trans-Golgi network membrane GO:0032588 9.83 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
14 endocytic vesicle membrane GO:0030666 9.8 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
15 early endosome membrane GO:0031901 9.78 HLA-C HLA-B HLA-A
16 transport vesicle membrane GO:0030658 9.77 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
17 recycling endosome membrane GO:0055038 9.74 HLA-C HLA-B HLA-A
18 phagocytic vesicle membrane GO:0030670 9.73 HLA-C HLA-B HLA-A
19 clathrin-coated endocytic vesicle membrane GO:0030669 9.72 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
20 MHC class I protein complex GO:0042612 9.65 HLA-C HLA-B HLA-A
21 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.56 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C
22 MHC class II protein complex GO:0042613 9.55 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
23 ER to Golgi transport vesicle membrane GO:0012507 9.23 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C

Biological processes related to Pityriasis Rosea according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.02 HLA-DRB5 HLA-DRB1 HLA-C HLA-B HLA-A CD1E
2 regulation of immune response GO:0050776 9.91 HLA-C HLA-B HLA-A CD40LG CD1A
3 adaptive immune response GO:0002250 9.91 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-C HLA-B
4 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.8 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1
5 T cell receptor signaling pathway GO:0050852 9.8 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-A
6 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.77 HLA-C HLA-B HLA-A
7 type I interferon signaling pathway GO:0060337 9.75 HLA-C HLA-B HLA-A
8 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.7 HLA-C HLA-B HLA-A
9 detection of bacterium GO:0016045 9.67 HLA-DRB1 HLA-B HLA-A
10 positive regulation of T cell mediated cytotoxicity GO:0001916 9.67 HLA-B HLA-A CD1E CD1A
11 immune response GO:0006955 9.65 HLA-DRB5 HLA-DRB1 HLA-DQB1 HLA-C HLA-B HLA-A
12 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.63 HLA-C HLA-B HLA-A
13 antigen processing and presentation GO:0019882 9.63 HLA-DRB5 HLA-DRB1 HLA-DQB1 HLA-C HLA-B HLA-A
14 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.61 HLA-C HLA-B HLA-A
15 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.6 HLA-DRB5 HLA-DRB1
16 antigen processing and presentation, exogenous lipid antigen via MHC class Ib GO:0048007 9.58 CD1E CD1A
17 protection from natural killer cell mediated cytotoxicity GO:0042270 9.57 HLA-B HLA-A
18 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.56 HLA-DRB1 HLA-DQB1
19 antigen processing and presentation, endogenous lipid antigen via MHC class Ib GO:0048006 9.55 CD1E CD1A
20 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.54 HLA-DRB1 HLA-DQB1
21 interferon-gamma-mediated signaling pathway GO:0060333 9.23 HLA-DRB5 HLA-DRB4 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C

Molecular functions related to Pityriasis Rosea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopeptide binding GO:0071723 9.37 CD1E CD1A
2 MHC class II receptor activity GO:0032395 9.33 HLA-DRB3 HLA-DRB1 HLA-DQB1
3 exogenous lipid antigen binding GO:0030884 9.32 CD1E CD1A
4 endogenous lipid antigen binding GO:0030883 9.26 CD1E CD1A
5 peptide antigen binding GO:0042605 9.17 HLA-DRB5 HLA-DRB3 HLA-DRB1 HLA-DQB1 HLA-C HLA-B
6 TAP binding GO:0046977 9.13 HLA-C HLA-B HLA-A

Sources for Pityriasis Rosea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....